Lexaria Bioscience (LEXX) EPS (Basic) (QoQ) (2015 - 2026)
Lexaria Bioscience (LEXX) EPS (Basic) (QoQ) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 43.73% |
| Feb 28, 2026 | -19.65% |
| Nov 30, 2025 | -54.91% |
| Aug 31, 2025 | -28.95% |
| May 31, 2025 | 38.33% |
| Feb 28, 2025 | -54.08% |
| Nov 30, 2024 | 112.90% |
| Aug 31, 2024 | 146.26% |
| May 31, 2024 | 133.09% |
| Feb 29, 2024 | -57.96% |
| Nov 30, 2023 | -26.93% |
| Aug 31, 2023 | -51.31% |
| May 31, 2023 | 70.57% |
| Feb 28, 2023 | 174.03% |
| Nov 30, 2022 | -18.34% |
| Aug 31, 2022 | 37.73% |
| May 31, 2022 | -266.01% |
| Feb 28, 2022 | 169.30% |
| Nov 30, 2021 | -29.74% |
| Aug 31, 2021 | 46.45% |